» Articles » PMID: 25115926

Role of the Water-metal Ion Bridge in Mediating Interactions Between Quinolones and Escherichia Coli Topoisomerase IV

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2014 Aug 14
PMID 25115926
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Although quinolones have been in clinical use for decades, the mechanism underlying drug activity and resistance has remained elusive. However, recent studies indicate that clinically relevant quinolones interact with Bacillus anthracis (Gram-positive) topoisomerase IV through a critical water-metal ion bridge and that the most common quinolone resistance mutations decrease drug activity by disrupting this bridge. As a first step toward determining whether the water-metal ion bridge is a general mechanism of quinolone-topoisomerase interaction, we characterized drug interactions with wild-type Escherichia coli (Gram-negative) topoisomerase IV and a series of ParC enzymes with mutations (S80L, S80I, S80F, and E84K) in the predicted bridge-anchoring residues. Results strongly suggest that the water-metal ion bridge is essential for quinolone activity against E. coli topoisomerase IV. Although the bridge represents a common and critical mechanism that underlies broad-spectrum quinolone function, it appears to play different roles in B. anthracis and E. coli topoisomerase IV. The water-metal ion bridge is the most important binding contact of clinically relevant quinolones with the Gram-positive enzyme. However, it primarily acts to properly align clinically relevant quinolones with E. coli topoisomerase IV. Finally, even though ciprofloxacin is unable to increase levels of DNA cleavage mediated by several of the Ser80 and Glu84 mutant E. coli enzymes, the drug still retains the ability to inhibit the overall catalytic activity of these topoisomerase IV proteins. Inhibition parallels drug binding, suggesting that the presence of the drug in the active site is sufficient to diminish DNA relaxation rates.

Citing Articles

Three Dihydroquinolin-4-one Derivatives as Potential Biodiesel Additives: From the Molecular Structure to Machine Learning Approach.

de Almeida L, Aguiar A, da Anunciacao A, dOliveira G, Vaz W, Custodio J ACS Omega. 2024; 9(50):49188-49204.

PMID: 39713672 PMC: 11656225. DOI: 10.1021/acsomega.4c05742.


Antibacterial Mechanisms and Clinical Impact of Sitafloxacin.

Kuhn E, Sominsky L, Chitto M, Schwarz E, Moriarty T Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598446 PMC: 11597390. DOI: 10.3390/ph17111537.


Highly sensitive mapping of in vitro type II topoisomerase DNA cleavage sites with SHAN-seq.

Morgan I, McKie S, Kim R, Seol Y, Xu J, Harami G Nucleic Acids Res. 2024; 52(16):9777-9787.

PMID: 39106172 PMC: 11381365. DOI: 10.1093/nar/gkae638.


Highly sensitive mapping of type II topoisomerase DNA cleavage sites with SHAN-seq.

Morgan I, McKie S, Kim R, Seol Y, Xu J, Harami G bioRxiv. 2024; .

PMID: 38798569 PMC: 11118536. DOI: 10.1101/2024.05.17.594727.


Interactions between Gepotidacin and Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting.

Oviatt A, Gibson E, Huang J, Mattern K, Neuman K, Chan P ACS Infect Dis. 2024; 10(4):1137-1151.

PMID: 38606465 PMC: 11015057. DOI: 10.1021/acsinfecdis.3c00346.


References
1.
Pan X, Ambler J, Mehtar S, Fisher L . Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996; 40(10):2321-6. PMC: 163528. DOI: 10.1128/AAC.40.10.2321. View

2.
Fournier B, Zhao X, Lu T, Drlica K, Hooper D . Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob Agents Chemother. 2000; 44(8):2160-5. PMC: 90029. DOI: 10.1128/AAC.44.8.2160-2165.2000. View

3.
Aldred K, Schwanz H, Li G, McPherson S, Turnbough Jr C, Kerns R . Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem Biol. 2013; 8(12):2660-8. PMC: 3870039. DOI: 10.1021/cb400592n. View

4.
Deweese J, Osheroff N . The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 2008; 37(3):738-48. PMC: 2647315. DOI: 10.1093/nar/gkn937. View

5.
Pan X, Fisher L . DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998; 42(11):2810-6. PMC: 105948. DOI: 10.1128/AAC.42.11.2810. View